IP Library Granted Patent US 6,964,846
Granted Patent B1
US 6,964,846 · App. 09/545,162 · Granted Nov 15, 2005

Methods for detecting nucleic acids indicative of cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,964,846
App. No.
09/545,162
Granted
Nov 15, 2005
Kind
B1
Abstract

The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer. Method are provided for screening a patient for cancer or precancer by detecting the presence of nucleic acid fragments that are longer than nucleic acid fragments expected to be present in a sample obtained from a healthy individual. In one embodiment, a positive screen for cancer or precancer is identified when a patient tissue or body fluid sample comprising exfoliated cells or cellular debris contains an amount of nucleic acid of a length greater than about 200 base pairs that exceeds a predetermined amount.

Claims (13)

1. A method for screening a patient for a colorectal cancer or a colorectal precancer, the method comprising the steps of:

detecting in a patient stool sample comprising exfoliated cells or cellular debris a first amount of a long nucleic acid of a length greater than 200 base pairs in length; wherein said long nucleic acid is present in both normal and cancerous or precancerous cells;

comparing the first amount of long nucleic acid in said patient stool sample to a second amount of said long nucleic acid present in a stool sample from patient free of colorectal cancer or precancer;

determining whether said first amount of long nucleic acid exceeds the second amount of long nucleic acid in said sample from a patient free of colorectal cancer or precancer; and;

identifying a positive screen for an indicator of a colorectal cancer or precancer if said amount of long nucleic acid in said patient stool sample does exceed said second amount of long nucleic acid in said sample from a patient free of colorectal cancer or precancer.

2. The method for screening a patient for a colorectal cancer or a colorectal precancer, the method comprising the steps of:

determining in patient stool sample comprising exfoliated cells or cellular debris a first amount of long nucleic acid of a length greater then 200 base pairs;

determining in said stool sample a second amount of nucleic acid of a length less than said long nucleic acid;

determining a ratio between said first amount and said amount; and identifying a positive screen for an indicator of a colorectal cancer or precancer if said ratio exceeds a

threshold ratio for patient who do not have a colorectal cancer or a precancer.

3. The method of claim 1 or claim 2 , wherein said detecting or determining comprises conducting an amplification reaction designed to amplify only nucleic acids fragments that are greater than 200 base pair in length.

4. The method of claim 1 or claim 2 , further comprising the step of enriching said sample for human DNA.

5. The method of claim 1 or claim 2 , further comprising the step of isolating human DNA from said sample.

Assignments (5)
MERGER Recorded Jan 14, 2022
From: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 058738/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: EXACT SCIENCES CORPORATION
To: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
Reel/Frame 044119/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2014
From: ESOTERIX GENETIC LABORATORIES, LLC
To: EXACT SCIENCES CORPORATION
Reel/Frame 032325/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2011
From: GENZYME CORPORATION
To: ESOTERIX GENETIC LABORATORIES, LLC
Reel/Frame 025656/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2009
From: EXACT SCIENCES CORPORATION
To: GENZYME CORPORATION
Reel/Frame 022460/0934 →